ESSENTIALS OF DIAGNOSIS
Chronic itching and scratching.
Lichenified lesions with exaggerated skin lines overlying a thickened, well-circumscribed, scaly plaque.
Predilection for nape of neck, wrists, external surfaces of forearms, lower legs, and genitals.
Lichen simplex chronicus represents a self-perpetuating scratch-itch cycle that is hard to disrupt.
Intermittent itching incites the patient to scratch the lesions and may interfere with sleep. Dry, hypertrophic, lichenified plaques appear on the neck, wrists, ankles, or perineum (Figure 6–21) (eFigure 6–66) (eFigure 6–67). The patches are rectangular, thickened, and hyperpigmented. The skin lines are exaggerated.
Lichen simplex chronicus. (Used, with permission, from TG Berger, MD, Dept Dermatology, UCSF.)
Lichen simplex chronicus resulting from repeated itch-scratch cycles. Note the hypertrophic leathery, lichenified plaques. The exaggerated skin lines are characteristic. (Used, with permission, from S Goldstein, MD.)
Lichen simplex chronicus on the hand. (Used, with permission, from Lindy Fox, MD.)
This disorder can be differentiated from plaque-like lesions such as psoriasis (redder lesions having whiter scales on the elbows, knees, and scalp and nail findings) (Figure 6–22), lichen planus (violaceous, usually smaller polygonal papules), and nummular (coin-shaped) dermatitis (eFigure 6–68). Lichen simplex chronicus may complicate chronic atopic dermatitis or scabetic infestation.
Nummular dermatitis. (Used, with permission, from Lindy Fox, MD.)
For lesions in extragenital regions, ultra-high potency topical corticosteroids are effective, with or without occlusion, when used twice daily for several weeks (Table 6–2). In some patients, flurandrenolide (Cordran) tape may be effective, since it prevents scratching and rubbing of the lesion. The injection of triamcinolone acetonide suspension (5–10 mg/mL) into the lesions may occasionally be curative. Continuous occlusion with a flexible hydrocolloid dressing for 7 days at a time for 1–2 months may also be helpful. Dupilumab is a new treatment option for generalized disease or prurigo nodularis, its related condition. For genital lesions, see the section Pruritus Ani.
The disease tends to remit during treatment but may recur or develop at another site.
et al; French Group of Research and Study in Atopic Dermatitis (Groupe de Recherche sur l’Eczéma Atopique, GREAT) from the French Society of Dermatology (SFD). Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients. ...